Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 12/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4739176 | 0.72 | TSHR (0.50) | APLNRALDH1A1MAPTNPSR1CYP2C9 | |
| SCHEMBL4742652 | 0.71 | APLNR (0.54) | APLNRALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL4737051 | 0.71 | BCL2 (0.55) | ALDH1A1MEN1KMT2AMAPTRECQL | |
| SCHEMBL3668406 | 0.69 | KDM4E (0.38) | KDM4E | |
| SCHEMBL4741286 | 0.67 | MAPT (0.36) | APLNRALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL4739135 | 0.66 | ALDH1A1 (0.52) | L3MBTL1ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL4739120 | 0.65 | MAPT (0.49) | L3MBTL1ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL5000196 | 0.63 | ALDH1A1 (0.59) | L3MBTL1ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL4859194 | 0.63 | POLB (0.44) | L3MBTL1ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL2297785 | 0.63 | CHEK1 (0.36) | KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008089051-A1 | N-SUBSTITUTED GLYCINE DERIVATIVES: PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-24 | — | — | WO | disclosed |
| US-20080171756-A1 | N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171756-A1 | N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN2, EGLN3 | APLNR 2034/4885L3MBTL1 2580/4885ALDH1A1 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.